Detalles de la búsqueda
1.
Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg-Depleting Antibody.
Clin Pharmacol Ther
; 2024 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38769868
2.
CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia.
Front Oncol
; 13: 1150149, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37205201
3.
Selective targeting of IL2Rßγ combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC.
Cell Rep Med
; 4(8): 101150, 2023 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37586327
4.
Simultaneous targeting of PD-1 and IL-2Rßγ with radiation therapy inhibits pancreatic cancer growth and metastasis.
Cancer Cell
; 41(5): 950-969.e6, 2023 05 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37116489
5.
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.
Nat Med
; 29(3): 632-645, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36928817
6.
Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors.
Nat Commun
; 13(1): 7015, 2022 11 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36385142
7.
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer.
J Immunother Cancer
; 8(2)2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32616554
8.
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.
Nat Cancer
; 1(12): 1153-1166, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33644766
9.
The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment.
Cancer Res
; 80(13): 2903-2913, 2020 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32409308
10.
Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans.
Cancer Immunol Immunother
; 58(1): 95-109, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18594818
11.
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.
Sci Transl Med
; 11(496)2019 06 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31189721
12.
CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
MAbs
; 6(6): 1571-84, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25484061
13.
Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release.
J Immunother
; 32(5): 452-64, 2009 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19609237
14.
Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.
Cancer Res
; 68(1): 143-51, 2008 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18172306
Resultados
1 -
14
de 14
1
Próxima >
>>